Market Research Report
Global Hypopigmentation Disorder Treatment Market - 2019-2026
|Published by||DataM Intelligence||Product code||834568|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Hypopigmentation Disorder Treatment Market - 2019-2026|
|Published: May 1, 2019||Content info: 130-180 Pages||
The natural coloring of a human or animal's skin is known as pigmentation. Pigmentation disorders are caused by a change in the level of melanin, a pigment produced by melanocytes. Pigmentation disorders affect the skin color causing the skin to appear as discolored and blotchy. The formation of pigmented skins may occur in patches all over the body. Pigmentation disorders cause a large number of heterogeneous conditions because of altered melanocyte density and melanin concentration. Hypopigmentation is patches of skin that are lighter than the overall skin tone. Hypopigmentation is caused by the absence of a normal amount of melanin because of disease, injury, burns, or other trauma. Hypopigmentation disorders include vitiligo and albinism. Treatments of this disease include topical drugs, laser therapy, chemical peels, microdermabrasion, and phototherapy.
According to the United Nations (UN) estimates, albinism is present in one out of 17,000 to 20,000 people in North America and Europe. In Africa one in every 5,000 to 15,000 people have albinism. Prevalence of albinism is high in African nations. Although, hypopigmentation may occur among people of all races, the occurrence of such a condition is more noticeable among individuals with a dark complexion.
The global hypopigmentation disorder treatment market was worth $XX million in 2018 and is forecasted to reach $XX million by 2026, at a CAGR of XX% during the forecast period.
The major drivers fueling the growth of the market are rise in prevalence of vitiligo and albinism, increase in awareness about hypopigmentation disorders, increase in health care expenditure, rich product pipeline, and rise in the number of clinical trials
According to the Global Vitiligo Foundation, in 2017, around 70 million people across the world had vitiligo. Vitiligo is a persistent condition and very hard to treat. Many major companies have a strong pipeline of hypopigmentation therapeutics. Hypopigmentation is an autoimmune disorder. In people with Hypopigmentation, the immune system appears to attack the pigment cells (melanocytes) in the skin. About 15 to 25 percent of people with vitiligo are also affected by at least one other autoimmune disorder, particularly autoimmune thyroid disease, rheumatoid arthritis, type 1 diabetes, psoriasis, pernicious anemia, Addison disease, or systemic lupus erythematosus.
High cost, complications, and risks associated with medical aesthetics product and treatment
are going to restrain the market in the forecast period.
The global hypopigmentation disorder treatment market can be segmented by treatment as topical drugs, laser therapy, chemical peels, microdermabrasion, and others, by disease indication as vitiligo, albinism, and others and by end-user as hospitals, aesthetic clinics & dermatology centers, and others.
By disease indication, vitiligo is expected to dominate the global hypopigmentation market in the period of forecast. According to the American Academy of Dermatology, vitiligo is considered to be among 24 skin diseases, which are widely prevalent among the population. Although, vitiligo is known to affect individuals from all ethnic background and genders equivalent but the prevalence of the same is more prominent among individuals between the age of 10 and 30 years. Moreover, as per Centre for Disease Control and Prevention (CDC), in 2013, it was estimated that more than 150,000 Americans from all age groups underwent treatment for vitiligo.
Geographically, the global hypopigmentation disorder treatment market is divided into North America, Europe, South America, Asia-Pacific and the Middle East and Africa.
The market in North America is driven by an increase in the incidence of hypopigmentation disorders, new product approvals, strong product pipeline, and a rise in health care expenditure. According to the National Organization for Albinism and Hypopigmentation, about one in 20,000 people have some type of albinism in the United States. Advancement in cosmetic therapy such as laser resurfacing and ongoing research and development on pigmentation disorder treatment and surgeries are boosting the market growth.
The hypopigmentation disorder treatment market in the Asia Pacific is anticipated to expand at a rapid pace during the forecast period because of rising disposable income and changing lifestyle. China has a high population of patients with vitiligo. According to the World Health Organization (WHO), around 0.6% of the total population in China suffers from hypopigmentation disorder.
Some of the key players in the hypopigmentation disorder market are Allergan, SkinCeuticals, Pierre Fabre, Episciences, Inc., RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC (Obagi Medical), and Alvogen.
In September 2018, Allergan Plc agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications.